Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports First Quarter 2024 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 1, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-over-year to $677.7 million, compared to $506.9 million in the first quarter of 2023. “The first quarter of 2024 re ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-19847 ...

United Therapeutics (UTHR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The ...

公司活动 - United Therapeutics公司宣布Patrick Poisson将在Leerink Partners Global Biopharma Conference 2024上进行公司运营概述和更新[1] - 会议将于2024年3月12日下午1:40至2:10在美国佛罗里达州迈阿密海滩举行，并可通过United Therapeutics网站上的直播网络研讨会访问[2] 公益使命 - United Therapeutics是一家公益公司，致力于创新满足患者未满足的医疗需求，并通过开发新型药物疗法和技术扩大可移植器官的供应来实现公益目的[3] - 公司的前瞻性声明受到私人证券诉讼改革法案的约束，包括努力为患者未满足的医疗需求创新，造福其他利益相关者，追求开发新型药物疗法和扩大可移植器官供应的公益目的[4]

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s operations during a fireside chat session at the TD Cowen 44th Annual Health Care Conference in Boston. The session will take place on Tuesday, March 5, 2024, from 12:50 p.m. to 1:20 p.m., Eastern Standard Time, and can be accessed v ...

United Therapeutics‘ (UTHR) fourth-quarter 2023 earnings of $4.36 per share beat the Zacks Consensus Estimate of $3.92. Earnings rose 63% year over year on the back of higher product sales.Revenues in the reported quarter were $614.7 million, beating the Zacks Consensus Estimate of $562 million. Revenues rose 25% year over year, driven by Tyvaso sales.Quarter in DetailUnited Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Remodulin, Tyvaso, Adcirca and Orenitram. It also marke ...

United Therapeutics (UTHR) closed the last trading session at $219.18, gaining 0.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $290.92 indicates a 32.7% upside potential.The mean estimate comprises 13 short-term price targets with a standard deviation of $50.38. While the lowest estimate of $178 indicates a 18.8% decline from the current price level, the most optimistic analys ...

财务数据和关键指标变化 - 公司在第四季度创下历史最高收入615百万美元,同比增长25%,全年收入超过23亿美元,同比增长20% [35] - Orenitram收入84百万美元,同比增长11%,主要受益于销量、价格和平均剂量的增加 [36] - 全球Remodulin收入115百万美元,同比下降6%,主要受国际订单时间影响,但美国Remodulin收入106百万美元,同比增长9% [37][38] - 全球Unituxin收入54百万美元,同比增长48%,美国收入49百万美元,同比增长34%,主要受益于定价和销量增加 [39][40] - 全球Tyvaso收入351百万美元,同比增长45%,创历史新高,美国收入337百万美元,同比增长40%,主要受益于Tyvaso DPI的持续渗透 [41] 各条业务线数据和关键指标变化 - Orenitram收入增长受益于销量、价格和平均剂量的增加 [36] - Remodulin在美国市场保持领先地位,美国收入增长9% [37][38] - Unituxin在美国和国际市场均实现强劲增长,主要受益于定价和销量 [39][40] - Tyvaso系列产品在PAH和PH-ILD市场保持领先地位,Tyvaso DPI持续渗透推动收入增长 [41][45] 各个市场数据和关键指标变化 - 美国市场是公司主要收入来源,Remodulin、Unituxin和Tyvaso系列产品在美国均实现强劲增长 [37][39][41] - 国际市场Remodulin收入受订单时间影响有所下降,但Unituxin在日本市场表现强劲 [37][40] 公司战略和发展方向及行业竞争 - 公司未来发展战略包括:1)现有商业业务持续增长;2)近期管线推进,如TETON和ralinepag研究;3)长期通过器官移植技术解决终末期器官病患的需求 [12][15][16] - 公司在DPI产品Tyvaso DPI方面具有竞争优势,如单次吸入量少、一致性给药等 [48][49] - 新的激活素信号通路抑制剂产品预计将于今年3月获批,但公司认为其更多是作为补充而非替代现有前列环素治疗 [51][52] 管理层对经营环境和未来前景的评论 - 公司对现有商业业务的持续强劲增长以及近期管线的推进表示乐观 [12][33] - 管理层认为公司在DPI产品竞争中具有优势,并且新的激活素抑制剂产品不会对公司现有前列环素治疗产生重大影响 [48][51][52] - 公司长期看好通过器官移植技术解决终末期器官病患的需求,并已取得多项重要进展 [15][25][30] 问答环节重要的提问和回答 问题1 **Roanna Ruiz 提问** 询问Tyvaso系列产品的患者需求情况以及库存动态 [62] **Michael Benkowitz 回答** - 第四季度Tyvaso系列产品的患者需求指标保持强劲,新增患者数创纪录 - 由于季节性因素,第四季度新增患者转化率略有下降,但在第一季度已经得到拉动 - 公司与合作伙伴MannKind的产能扩张计划保证了Tyvaso DPI的供应,未来不会出现供应瓶颈 [64][65][66][67] 问题2 **Ash Verma 提问** 1) 询问公司Xeno器官移植项目的临床试验设计 2) 询问Tyvaso DPI在通过通胀减免法案后患者自付费用的变化情况 [71] **Leigh Peterson 回答** 公司正在进行Xeno器官移植的IND使能研究,计划于2025年启动10基因Xeno肾和Xeno心脏的临床试验 [73] **Michael Benkowitz 回答** - 通胀减免法案将大幅降低患者自付费用,公司预计未来患者援助计划的使用将逐步下降 - 这将有利于Tyvaso DPI的使用,缓解之前由于自付费用高而造成的障碍 [77][78][79] 问题3 **Joseph Thome 提问** 询问公司如何披露Xeno器官移植项目的关键性前体临床试验数据 [92] **Martine Rothblatt 回答** - 公司会尽可能在顶级期刊上发表相关研究成果,如即将发表的综述文章 - 每次获得FDA批准进入下一阶段临床的消息,公司都会及时披露 [93][94][95]

United Therapeutics Corporation Fourth Quarter 2023 Financial Update 2 INTRODUCTION Safe Harbor Statement All statements in this presentation are made as of February 21, 2024. We undertake no obligation to publicly update or revise these statements, whether as a result of new information, future events or otherwise. Statements included in this presentation that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-lo ...

财务表现 - United Therapeutics在2023年第四季度报告的营收为6.147亿美元，同比增长25.1%[1] - 公司的每股收益为4.36美元，较去年同期的2.67美元有所增长[1] - 公司的营收超出了Zacks Consensus Estimate 9.42%，每股收益也超出了预期11.22%[2] - 公司在美国和其他地区的营收表现分别为585.90万美元和28.80万美元，与分析师的平均预期相比有所不同[6] 产品线表现 - 不同产品线的营收表现也有所不同，如Remodulin、Adcirca、Orenitram、Tyvaso和Unituxin[7][8][9] 股票表现 - United Therapeutics的股票在过去一个月中表现不佳，但目前具有Zacks Rank 2（买入），预示着在短期内可能会跑赢整个市场[10]